ByteDance's AI Pharmaceutical Business Split: A Leap from Algorithm Models to Industrial Applications
ByteDance officially initiates the spin-off and independent financing of its AI drug discovery business, marking a shift from R&D to industrialization. The new company, still majority-owned by ByteDance, integrates the core team, algorithm platform, and pipeline assets, with continued support from Volcano Engine's computing power. Established in 2021, this move deepens ByteDance's strategic expansion in biocomputing.....